SCHEMBL64601

SCHEMBL64601

OC[C@@H]1C[C@H](O)C[C@@H](O)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18824104 1.00
SCHEMBL12951886 1.00
SCHEMBL10330335 1.00
SCHEMBL1223496 1.00
SCHEMBL10033827 1.00
SCHEMBL24240747 1.00
SCHEMBL18823811 1.00
SCHEMBL12942702 1.00
SCHEMBL21323889 1.00
SCHEMBL4702039 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6878547-B1 Antisense oligonucleotides against tenascin for treating vitiligo AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-04-12 US claimed
EP-0653439-B1 Stabilized oligonucleotids and the use thereof AVENTIS PHARMA GMBH (DE) 2004-04-28 EP claimed
US-20020151512-A1 G cap-stabilized oligonucleotides SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-10-17 US claimed
JP-2002523335-A 2002-07-30 JP claimed
EP-1182206-A2 Stabilized oligonucleotids and the use thereof HOECHST AKTIENGESELLSCHAFT (DE) 2002-02-27 EP claimed
EP-0726274-B1 G-cap stabilized oligonucleotides AVENTIS PHARMA GMBH (DE) 2001-10-10 EP claimed
US-20010021772-A1 SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-09-13 US claimed
EP-1102842-A2 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION Aventis Pharma Deutschland GmbH (DE) 2001-05-30 EP claimed
EP-1100894-A2 SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION Aventis Pharma Deutschland GmbH (DE) 2001-05-23 EP claimed
WO-2000008140-A2 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-02-17 WO claimed
WO-2000008141-A2 SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-02-17 WO claimed
EP-0979869-A1 Short oligonucleotides for the inhibition of VEGF expression Hoechst Marion Roussel Deutschland GmbH (DE) 2000-02-16 EP claimed
EP-0978561-A1 Antisense oligonucleotides for the inhibition of VEGF expression Hoechst Marion Roussel Deutschland GmbH (DE) 2000-02-09 EP claimed
US-6013639-A MODIFYING END GROUPS; DIAGNOSIS, THERAPY CANCER, RESTENOSIS HOECHST AKTIENGESELLSCHAFT (DE) 2000-01-11 US claimed
EP-0726274-A2 G-cap stabilized oligonucleotides HOECHST AKTIENGESELLSCHAFT (DE) 1996-08-14 EP claimed
EP-0653439-A2 Stabilized oligonucleotids and the use thereof HOECHST AKTIENGESELLSCHAFT (DE) 1995-05-17 EP claimed
US-20240084287-A1 SINGLE CELL CELLULAR COMPONENT ENRICHMENT FROM BARCODED SEQUENCING LIBRARIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-03-14 US disclosed
US-20240018455-A1 DNA ORIGAMI CELL SENSING PLATFORM OHIO STATE INNOVATION FOUNDATION 2024-01-18 US disclosed
EP-0726274-A2 G-cap stabilized oligonucleotides HOECHST AKTIENGESELLSCHAFT (DE) 1996-08-14 EP disclosed
EP-0653439-A2 Stabilized oligonucleotids and the use thereof HOECHST AKTIENGESELLSCHAFT (DE) 1995-05-17 EP disclosed